IL1B and nasopharyngeal carcinoma: Importantly, we demonstrate that therapeutic treatment activates the inflammasome in NPC cells and can enhance IL-1β production (from ∼174 to ∼492 pg/ml) in the presence of tumour microenvironmental factors (Fig 4I).